:

Colorectal
Cancer

Contact an Amgen Medical Information Healthcare Professional to learn about ongoing clinical trials.

Why is the CodeBreaK 300 clinical trial being done?

The purpose of the CodeBreaK 300 clinical trial is to evaluate the effectiveness and safety of study drugs, known as sotorasib and panitumumab versus either trifluridine and tipiracil or regorafenib. The study includes patients with colorectal cancer whose tumors have the KRAS G12C mutation. The colorectal cancer in these patients has spread to other parts of the body (metastatic), and they have already received treatments.

CodeBreaK 300: Colorectal Cancer

NCT05198934

If you’re interested in the CodeBreaK clinical trial, you can print this page and show it to your doctor or give the above clinical trial reference number to your doctor.

Who can participate?

A study doctor will determine the eligibility of each potential participant. If you fit the profile below, the CodeBreaK 300 clinical trial might be an option for you.

clinical-trail-6.png

Colorectal Cancer

Patients diagnosed with colorectal cancer that has spread to other parts of the body (metastatic) and who have already received treatments

clinical-trail-6.png

KRAS G12C Mutation

Patients whose colorectal cancer contains the KRAS G12C mutation

clinical-trail-6.png

Age

Patients who are age 18 years and older

doctor.png

Study participants must also meet additional eligibility criteria. For information about these criteria, please contact an Amgen Medical Information Healthcare Professional

How do I know if my cancer has the KRAS G12C mutation?

You may have already been tested for genetic mutations related to cancer. You can ask your doctor about this testing, which is called biomarker testing, to determine if your cancer has the KRAS G12C mutation. You or your doctor can also contact us for more information.

What are the study drugs?

All CodeBreaK 300 clinical trial participants will receive an active study drug—either sotorasib plus panitumumab, trifluridine plus tipiracil, or regorafenib*—during this clinical trial. The study drugs you receive are based on your assigned study group. Both you and the doctor will know which study drug(s) you receive.

meds.png

Sotorasib (oral tablets)

  • Once a day
  • In combination with panitumumab
  • Sotorasib is not currently FDA approved for colorectal cancer

AND

meds.png

Panitumumab (intravenous infusion)

  • Once every 2 weeks
  • In combination with sotorasib
  • Panitumumab* is FDA approved for colorectal cancer that has spread to other parts of the body, but not for the patients in this study

OR

meds.png

Trifluridine plus Tipiracil (oral tablets)

  • Twice a day on days 1–5 and days 8–12 of each 28-day cycle
  • Approved drug* (currently FDA approved for use in colorectal cancer that has spread to other parts of the body and for which they have received previous treatments)

OR

meds.png

Regorafenib (oral tablets)

  • Once a day for the first 21 days of each 28-day cycle
  • Approved drug* (currently FDA approved for use in colorectal cancer that has spread to other parts of the body and for which they have received previous treatments)
*For information about the specific anti-cancer therapies included in the CodeBreaK trials, please contact an Amgen Medical Information Healthcare Professional.

What happens in the CodeBreaK 300 clinical trial?

If you agree to join the CodeBreaK 300 clinical trial, you will go to the study clinic for assessments of your cancer and your overall health to find out if you meet all requirements for participation.

If you meet all requirements for participation and decide to continue, you will be assigned to a study group. The study group to which you are assigned will determine which treatment you will receive.

CodeBreaK 300 is a Phase 3 clinical trial.

  • About 153 study participants around the world will be enrolled for this trial

Timeline

Screening period (up to 4 weeks)

  • Attend a screening visit to provide medical history
  • Have medical testing done to see if you meet the requirements for participating in the CodeBreaK 300 clinical trial
Timeline

Study treatment period**

  • Receive your assigned study treatment of either sotorasib in combination with panitumumab, trifluridine plus tipiracil, or regorafenib
  • Attend study appointments and get imaging to monitor how your disease is responding to treatment

**The length of time for which you receive treatment will vary depending on how you respond to treatment.

Long-term follow up period (up to 1 year)

  • Talk to the study team by phone or visit the study clinic about every 3 months

Where can I get more information?

If you want more information about CodeBreaK clinical trials and whether you may be eligible for one of these clinical trials, please contact an Amgen Medical Information Healthcare Professional or talk to your doctor.

chat.png

AmgenMedInfo.com

866-572-6436 (866-57-AMGEN)

Monday–Friday 8am to 8pm (ET)

Contact Amgen